Target Details
| UniProt AC | P42345 |
|---|---|
| Gene Symbol | MTOR |
| Protein Name | Serine/threonine-protein kinase mTOR |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF02259 (FAT) PF02260 (FATC) PF08771 (FRB_dom) PF23593 (HEAT_ATR) PF11865 (mTOR_dom) PF00454 (PI3_PI4_kinase) |
Summary
- Multi-target molecules 2,517
- Clinical molecules 193
- Avg pChEMBL 7.75
KEGG Pathways (53)
- AMPK signaling pathway
- Acute myeloid leukemia
- Adipocytokine signaling pathway
- Alzheimer disease
- Amyotrophic lateral sclerosis
- Apelin signaling pathway
- Autophagy - animal
- Autophagy - other
- Breast cancer
- Cellular senescence
- Central carbon metabolism in cancer
- Chemical carcinogenesis - receptor activation
- Choline metabolism in cancer
- Colorectal cancer
- Diabetic cardiomyopathy
- EGFR tyrosine kinase inhibitor resistance
- Endocrine resistance
- ErbB signaling pathway
- Gastric cancer
- Glioma
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatocellular carcinoma
- Herpes simplex virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- Huntington disease
- Insulin resistance
- Insulin signaling pathway
- Integrin signaling
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Longevity regulating pathway
- Longevity regulating pathway - multiple species
- Lysosome biogenesis
- MicroRNAs in cancer
- Neutrophil extracellular trap formation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Phospholipase D signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Shigellosis
- Spinocerebellar ataxia
- Th17 cell differentiation
- Thermogenesis
- Thyroid hormone signaling pathway
- Type II diabetes mellitus
- mTOR signaling pathway
Associated Diseases (2)
Active Molecules (2,517)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
XMDPZWNVQRMVKQ
|
9.2 | IC50 | 3 | — | |
ZAEPCTWTCFBKRF
|
9.2 | IC50 | 2 | — | |
KFBFILUFBJUNRT
|
9.2 | IC50 | 2 | — | |
MTJZTDDVRCDUJY
|
9.2 | IC50 | 2 | — | |
CDVMSFKGTWBIBF
|
9.2 | IC50 | 3 | — | |
CSEOONOVPLSZSS
|
9.2 | IC50 | 4 | — | |
VPLAAHHOBJVHMP
|
9.2 | IC50 | 3 | — | |
JAMULYFATHSZJM
|
9.2 | pIC50 | 7 | Yes | |
WZONDMPQOSFVCH
|
9.2 | IC50 | 2 | — | |
CRGQBIGNXMYDSX
|
9.2 | Ki | 2 | — | |
NDNACJXZRUEIIA
|
9.2 | IC50 | 2 | — | |
SRNMUDAJXGNOIO
|
9.2 | IC50 | 5 | — | |
FKSJHWZVXJQMHU
|
9.2 | IC50 | 2 | — | |
HBUWXCRVXVUSIE
|
9.2 | IC50 | 2 | — | |
LRSQBMMOLVJBMX
|
9.2 | IC50 | 2 | — | |
PGXJHBPGPCVGNZ
|
9.2 | IC50 | 2 | — | |
RNBNWTNJAHJTMI
|
9.2 | IC50 | 2 | — | |
VAXOTKGRKVHQLH
|
9.2 | IC50 | 3 | — | |
XOUWSDVICNCAQJ
|
9.2 | IC50 | 2 | — | |
QFJCIRLUMZQUOT
|
9.2 | IC50 | 9 | — | |
DOXIAEMKVAGAES
|
9.2 | IC50 | 2 | — | |
DTJDTFBMPVOAPF
|
9.2 | IC50 | 3 | — | |
FDKPZFVLRXGWLQ
|
9.2 | IC50 | 2 | — | |
FTALCBNCXWPPIP
|
9.2 | IC50 | 2 | — | |
FTRSKAKWKUDZKU
|
9.2 | IC50 | 2 | — | |
IRCGXDFJTQYSNR
|
9.2 | IC50 | 5 | — | |
JJPCSTPDDPYYQW
|
9.2 | IC50 | 3 | — | |
NNTLLIDAXIUUPO
|
9.2 | IC50 | 3 | — | |
QSRAFHYPMDCEPG
|
9.2 | IC50 | 3 | — | |
RRNFUKFNHGBQEF
|
9.2 | IC50 | 2 | — | |
SZQLHKIRUFFCBS
|
9.2 | IC50 | 2 | — | |
VKSCSFHLPAAEGS
|
9.2 | IC50 | 2 | — | |
WGJCAXDRPIQKGH
|
9.2 | IC50 | 2 | — | |
HWDAPNZBEKEDCW
|
9.1 | IC50 | 2 | — | |
UIILWXMACMFYIS
|
9.1 | IC50 | 2 | — | |
XJKQXGOQMQUXFR
|
9.1 | IC50 | 3 | — | |
ZXQLGEUAOSGDJY
|
9.1 | IC50 | 2 | — | |
BOWNHBOPRXQQHZ
|
9.1 | IC50 | 2 | — | |
DPFONBIFXAOZIL
|
9.1 | IC50 | 2 | — | |
RZERWDKPRCXFKM
|
9.1 | IC50 | 2 | — | |
BMHREZWGYXVBCN
|
9.1 | IC50 | 2 | — | |
QKAALDVCXLSPCV
|
9.1 | IC50 | 2 | — | |
URYMFNIQUUIFIY
|
9.1 | IC50 | 3 | — | |
YTOAJUIMCNAYNE
|
9.1 | IC50 | 5 | — | |
BWFWDKCSCQHZLJ
|
9.1 | IC50 | 2 | — | |
DARFQBXATOBEAV
|
9.1 | IC50 | 3 | — | |
HGZCDZAZJVNMKO
|
9.1 | IC50 | 5 | — | |
JFQAJQVVYSVHIZ
|
9.1 | pIC50 | 2 | Yes | |
KUARKKJFJBPZHD
|
9.1 | IC50 | 2 | — | |
KVLFRAWTRWDEDF
|
9.1 | IC50 | 5 | — |